Search This Blog

Friday, May 6, 2022

Raymond James maintains Strong Buy on ChemoCentryx

 ChemoCentryx Inc 

 (Get Free Alerts for CCXI) shares are trading higher by 21.45% at $19.00 after the company reported first-quarter results.

ChemoCentryx reported quarterly losses of 55 cents per share which missed the analyst consensus estimate of a loss of 30 cents. The company also reported quarterly sales of $5.46 million which missed the analyst consensus estimate of $22.04 million.

Raymond James analyst Steven Seedhouse maintained ChemoCentryx Friday morning with a Strong Buy and lowered the price target from $110 to $106.

https://www.benzinga.com/news/small-cap/22/05/27049457/why-chemocentryx-shares-are-popping-off

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.